Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples from Patients Infected with Omicron Variant.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Mar 2023
Historique:
received: 15 02 2023
accepted: 24 02 2023
entrez: 11 3 2023
pubmed: 12 3 2023
medline: 15 3 2023
Statut: epublish

Résumé

To compare the detection of the SARS-CoV-2 Omicron variant in nasopharyngeal-swab (NPS) and oral saliva samples. 255 samples were obtained from 85 Omicron-infected patients. SARS-CoV-2 load was measured in the NPS and saliva samples by using Simplexa™ COVID-19 direct and Alinity m SARS-CoV-2 AMP assays. Results obtained with the two diagnostic platforms showed very good inter-assay concordance (91.4 and 82.4% for saliva and NPS samples, respectively) and a significant correlation among cycle threshold (Ct) values. Both platforms revealed a highly significant correlation among Ct obtained in the two matrices. Although the median Ct value was lower in NPS than in saliva samples, the Ct drop was comparable in size for both types of samples after 7 days of antiviral treatment of the Omicron-infected patients. Our result demonstrates that the detection of the SARS-CoV-2 Omicron variant is not influenced by the type of sample used for PCR analysis, and that saliva can be used as an alternative specimen for detection and follow-up of Omicron-infected patients.

Identifiants

pubmed: 36902277
pii: ijms24054847
doi: 10.3390/ijms24054847
pmc: PMC10003189
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero della Salute
ID : Programme CCM 2020 Ricerca Corrente - Linea 1 on emerging and re-emerging infections
Organisme : European Commission
ID : CoNVat, Grant agreement ID 101003544; KRONO, Grant agreement ID 101005075; Grant Number SHARP: 848096

Références

Am J Infect Control. 2021 Sep;49(9):1165-1176
pubmed: 33774101
J Clin Virol Plus. 2022 Aug;2(3):100090
pubmed: 35693461
EBioMedicine. 2022 Sep;83:104232
pubmed: 35988466
J Clin Virol. 2020 Jul;128:104416
pubmed: 32388470
J Infect. 2021 Jul;83(1):e8-e10
pubmed: 34023366
Lancet Respir Med. 2021 Jun;9(6):562-564
pubmed: 33887248
Emerg Infect Dis. 2021 Apr;27(4):1146-1150
pubmed: 33754989
Front Public Health. 2021 May 21;9:589564
pubmed: 34150692
Science. 2021 Nov 19;374(6570):995-999
pubmed: 34648303
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Microbiol Spectr. 2022 Dec 21;10(6):e0222922
pubmed: 36409097
J Clin Virol. 2022 Jul;152:105170
pubmed: 35525108
J Med Virol. 2022 Oct;94(10):4704-4711
pubmed: 35642439
Viruses. 2020 Oct 20;12(10):
pubmed: 33092065
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Microbiol Spectr. 2022 Dec 21;10(6):e0252122
pubmed: 36318040
J Infect Chemother. 2021 Jul;27(7):1129-1130
pubmed: 33888419
J Clin Med. 2021 Apr 02;10(7):
pubmed: 33918294
JAMA Intern Med. 2021 Mar 1;181(3):353-360
pubmed: 33449069
Lancet Infect Dis. 2021 Oct;21(10):1354
pubmed: 34363772
Int J Infect Dis. 2022 Sep;122:401-404
pubmed: 35760381

Auteurs

Licia Bordi (L)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Giuseppe Sberna (G)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Eleonora Lalle (E)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Lavinia Fabeni (L)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Valentina Mazzotta (V)

Clinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Simone Lanini (S)

Clinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Angela Corpolongo (A)

Clinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Anna Rosa Garbuglia (AR)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Emanuele Nicastri (E)

Clinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Enrico Girardi (E)

Scientific Direction, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Francesco Vaia (F)

General and Health Management Direction, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Andrea Antinori (A)

Clinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Fabrizio Maggi (F)

Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH